Grand Pharmaceutical Group 과거 수익 실적
과거 기준 확인 2/6
Grand Pharmaceutical Group은 연평균 12.9%의 비율로 수입이 증가해 온 반면, Pharmaceuticals 산업은 수입이 증가했으며, 연간 5.7%였습니다. 매출은 연평균 12.8%의 비율로 증가했습니다. Grand Pharmaceutical Group의 자기자본이익률은 15.3%이고 순이익률은 22.7%입니다.
주요 정보
12.9%
수익 성장률
11.5%
EPS 성장률
| Pharmaceuticals 산업 성장 | 5.6% |
| 매출 성장률 | 12.8% |
| 자기자본 수익률 | 15.3% |
| 순이익 | 22.7% |
| 최근 수익 업데이트 | 30 Jun 2024 |
최근 과거 실적 업데이트
Recent updates
Grand Pharmaceutical Group Limited (HKG:512) Looks Inexpensive But Perhaps Not Attractive Enough
Sep 19
Grand Pharmaceutical Group (HKG:512) Is Paying Out A Larger Dividend Than Last Year
Jun 05Market Participants Recognise Grand Pharmaceutical Group Limited's (HKG:512) Earnings
May 22Grand Pharmaceutical Group (HKG:512) Will Pay A Larger Dividend Than Last Year At HK$0.26
Apr 25Grand Pharmaceutical Group (HKG:512) Will Pay A Larger Dividend Than Last Year At HK$0.26
Mar 25We Think Grand Pharmaceutical Group (HKG:512) Can Stay On Top Of Its Debt
Oct 20Here's Why We Think Grand Pharmaceutical Group (HKG:512) Is Well Worth Watching
Sep 26Grand Pharmaceutical Group's (HKG:512) Dividend Will Be Increased To HK$0.14
Jun 04Is Grand Pharmaceutical Group (HKG:512) A Risky Investment?
May 05Grand Pharmaceutical Group (HKG:512) Seems To Use Debt Quite Sensibly
Nov 21Is Grand Pharmaceutical Group Limited (HKG:512) Trading At A 43% Discount?
Sep 05Grand Pharmaceutical Group (HKG:512) Seems To Use Debt Quite Sensibly
Aug 16Here's Why We Think Grand Pharmaceutical Group (HKG:512) Is Well Worth Watching
Jul 28Grand Pharmaceutical Group's (HKG:512) Dividend Will Be HK$0.11
May 29Is Grand Pharmaceutical Group Limited (HKG:512) Trading At A 45% Discount?
Apr 08Grand Pharmaceutical Group (HKG:512) Has A Rock Solid Balance Sheet
Mar 22If You Like EPS Growth Then Check Out Grand Pharmaceutical Group (HKG:512) Before It's Too Late
Jan 24These 4 Measures Indicate That Grand Pharmaceutical Group (HKG:512) Is Using Debt Safely
Dec 13Grand Pharmaceutical Group Limited's (HKG:512) Intrinsic Value Is Potentially 45% Above Its Share Price
Nov 27With EPS Growth And More, China Grand Pharmaceutical and Healthcare Holdings (HKG:512) Is Interesting
Oct 25China Grand Pharmaceutical and Healthcare Holdings (HKG:512) Seems To Use Debt Rather Sparingly
Sep 01Do China Grand Pharmaceutical and Healthcare Holdings's (HKG:512) Earnings Warrant Your Attention?
Jul 12수익 및 비용 분석
수익 및 비용 분석
Grand Pharmaceutical Group 수익 창출 및 지출 방식. 최근 보고된 수익 기준, LTM 기준.
수익 및 매출 내역
| 날짜 | 수익 | 수익 | G+A 비용 | R&D 비용 |
|---|---|---|---|---|
| 30 Jun 24 | 10,587 | 2,409 | 3,744 | 0 |
| 31 Mar 24 | 10,558 | 2,144 | 3,802 | 0 |
| 31 Dec 23 | 10,530 | 1,880 | 3,860 | 0 |
| 30 Sep 23 | 10,434 | 2,139 | 3,822 | 0 |
| 30 Jun 23 | 10,339 | 2,398 | 3,783 | 0 |
| 31 Mar 23 | 9,951 | 2,239 | 3,579 | 0 |
| 31 Dec 22 | 9,562 | 2,079 | 3,374 | 0 |
| 30 Sep 22 | 9,403 | 1,995 | 3,386 | 0 |
| 30 Jun 22 | 9,244 | 1,910 | 3,399 | 0 |
| 31 Mar 22 | 8,921 | 2,156 | 3,359 | 0 |
| 31 Dec 21 | 8,598 | 2,403 | 3,319 | 0 |
| 30 Sep 21 | 8,131 | 2,340 | 3,223 | 0 |
| 30 Jun 21 | 7,664 | 2,277 | 3,126 | 0 |
| 31 Mar 21 | 7,008 | 2,035 | 2,836 | 0 |
| 31 Dec 20 | 6,353 | 1,793 | 2,545 | 0 |
| 30 Sep 20 | 6,306 | 1,558 | 2,534 | 0 |
| 30 Jun 20 | 6,259 | 1,323 | 2,523 | 0 |
| 31 Mar 20 | 6,425 | 1,237 | 2,686 | 0 |
| 31 Dec 19 | 6,591 | 1,151 | 2,849 | 0 |
| 30 Sep 19 | 6,450 | 1,048 | 2,688 | 0 |
| 30 Jun 19 | 6,309 | 944 | 2,526 | 0 |
| 31 Mar 19 | 6,134 | 828 | 2,419 | 0 |
| 31 Dec 18 | 5,958 | 713 | 2,312 | 0 |
| 30 Sep 18 | 5,845 | 642 | 2,364 | 0 |
| 30 Jun 18 | 5,732 | 570 | 2,415 | 0 |
| 31 Mar 18 | 5,251 | 516 | 2,141 | 0 |
| 31 Dec 17 | 4,771 | 461 | 1,867 | 0 |
| 30 Sep 17 | 4,480 | 413 | 1,728 | 0 |
| 30 Jun 17 | 4,190 | 364 | 1,590 | 0 |
| 31 Mar 17 | 3,943 | 317 | 1,457 | 0 |
| 31 Dec 16 | 3,696 | 269 | 1,324 | 0 |
| 30 Sep 16 | 3,573 | 241 | 1,245 | 0 |
| 30 Jun 16 | 3,450 | 213 | 1,167 | 0 |
| 31 Mar 16 | 3,348 | 197 | 1,119 | 0 |
| 31 Dec 15 | 3,246 | 181 | 1,071 | 0 |
| 30 Sep 15 | 3,158 | 187 | 1,021 | 0 |
| 30 Jun 15 | 3,071 | 194 | 971 | 0 |
| 31 Mar 15 | 3,097 | 185 | 976 | 0 |
| 31 Dec 14 | 3,122 | 175 | 981 | 0 |
| 30 Sep 14 | 3,040 | 150 | 932 | 0 |
| 30 Jun 14 | 2,958 | 126 | 884 | 0 |
| 31 Mar 14 | 2,808 | 113 | 828 | 0 |
| 31 Dec 13 | 2,658 | 100 | 772 | 0 |
양질의 수익: 512 은 높은 수익을 보유하고 있습니다.
이익 마진 증가: 512 의 현재 순이익 이익률 (22.7%) 작년보다 낮습니다 (23.2%).
잉여현금흐름 대 수익 분석
과거 수익 성장 분석
수익추이: 512 의 수입은 지난 5년 동안 매년 12.9% 씩 증가했습니다.
성장 가속화: 지난 1년간 512 의 수익 증가율( 0.4% )은 5년 평균( 12.9% 보다 낮습니다. 년도).
수익 대 산업: 지난 1년간 512 수익 성장( 0.4% )은 Pharmaceuticals 업계 6.4% 능가하지 못했습니다. 6.4%.
자기자본 수익률
높은 ROE: 512 의 자본 수익률( 15.3% )은 낮음으로 간주됩니다.